Low-dose Nrf2 agonists, for instance, bardoxolone methyl dh404, may attenuate atherosclerosis and reduce proteinuria, mesangial expansion and glomerular damage in diabetic nephropathy, although high-dose Nrf2 agonists may result in the expression of pro-inflammatory mediators such as monocyte chemoattractant protein-1 (MCP-1) and NF-κB [138]. The gene discussed is CCL2; the disease is diabetic kidney disease.